SHPG:NAS (Ireland) Also trade in: Austria Germany Mexico UK

Shire PLC

$ 179.2 0 (0%)
Volume: 0 Avg Vol (1m): 0
Market Cap $: 55.04 Bil Enterprise Value $: 70.19 Bil
P/E (TTM): 11.99 P/B: 1.50
Earnings Power Value 80.01
Net Current Asset Value -59.68
Tangible Book -36.53
Projected FCF 206.48
Median P/S Value 206.75
Graham Number 0
Peter Lynch Value 184.66
DCF (FCF Based) 312.17
DCF (Earnings Based) 159.87
YTD (-%)

Financial Strength : 5/10

Current vs industry vs history
Cash-to-Debt 0.01
Equity-to-Asset 0.59
Debt-to-Equity 0.41
Debt-to-EBITDA 2.75
Interest Coverage 7.65
Piotroski F-Score 6
0
1
2
3
4
5
6
7
8
9
Altman Z-Score 1.92
DISTRESS
GREY
SAFE
Beneish M-Score -2.24
Not Manipulator
Manipulator

Profitability & Growth : 9/10

Current vs industry vs history
Operating Margin % 25.91
Net Margin % 30.64
ROE % 13.33
ROA % 7.22
ROC (Joel Greenblatt) % 35.01
3-Year Total Revenue Growth Rate 43.20
3-Year Total EBITDA Growth Rate 13.60
3-Year EPS w/o NRI Growth Rate -0.70

» SHPG's 30-Y Financials

Financials (Next Earnings Date: 2019-04-26)

Guru Trades Click for details

» Details

Insider Trades

SEC Filings

Gurus Latest Trades with NAS:SHPG

» Interactive Chart

Peter Lynch Chart

Business Description

Industry Biotechnology » Biotechnology    NAICS : 325412    SIC : 2834
Compare NAS:BIIB ASX:CSL NAS:VRTX NAS:REGN XKRX:068270 XKRX:207940 NAS:CELG NAS:ALXN HKSE:01177 XMCE:GRF.P NAS:BMRN XBRU:UCB NAS:NKTR OCSE:NZYM B NAS:INCY OCSE:GEN NAS:BIVV HKSE:02269 NAS:JUNO NAS:ALNY
Traded in other countries S7E.Germany SHPG N.Mexico SHP.UK
Address
Shire is a diversified, Ireland-based specialty drug firm. Shire has grown primarily through mergers and acquisitions, including the Transkaryotic Therapies acquisition in 2005, which established its genetic disease business with Replagal and Elaprase, and the merger with New River in 2007, which brought full rights to neuroscience drug Vyvanse. Shire completed the acquisition of ViroPharma (genetic diseases) in 2014, NPS Pharma (internal medicine) in 2015, and Baxalta (hematology, immunology, and oncology) and Dyax (genetic diseases) in 2016.

Ratios

Current vs industry vs history
PE Ratio (TTM) 11.99
Forward PE Ratio 11.68
N/A
PE Ratio without NRI 11.99
Price-to-Owner-Earnings 15.89
PB Ratio 1.50
PS Ratio 3.67
Price-to-Free-Cash-Flow 16.34
Price-to-Operating-Cash-Flow 13.33
EV-to-EBIT 22.23
EV-to-EBITDA 12.81
EV-to-Revenue 4.67
PEG Ratio 0.78
Shiller PE Ratio 30.35
Current Ratio 0.92
Quick Ratio 0.51
Days Inventory 264.59
Days Sales Outstanding 76.56
Days Payable 323.67

Dividend & Buy Back

Current vs industry vs history
Dividend Yield % 0.59
Dividend Payout Ratio 0.07
3-Year Dividend Growth Rate (Per Share) 19.90
Forward Dividend Yield % 0.59
N/A
Yield-on-Cost (5-Year) % 1.72
3-Year Share Buyback Rate -15.60

Valuation & Return

Current vs industry vs history
Price-to-Projected-FCF 0.87
Price-to-DCF (Earnings Based) 1.12
Price-to-Median-PS-Value 0.87
Price-to-Peter-Lynch-Fair-Value 0.97
Earnings Yield (Joel Greenblatt) % 4.50
Forward Rate of Return (Yacktman) % 18.23

More Statistics

Revenue (TTM) (Mil) $ 15,701.8
EPS (TTM) $ 15.75
Beta 0
Volatility % 24.46
52-Week Range $ 123.73 - 182.47
Shares Outstanding (Mil) 306.04

Analyst Estimate

Piotroski F-Score Details

Piotroski F-Score 6
Positive ROA Y
Positive CFROA Y
Higher ROA yoy Y
CFROA > ROA N
Lower Leverage yoy Y
Higher Current Ratio yoy N
Less Shares Outstanding yoy N
Higher Gross Margin yoy Y
Higher Asset Turnover yoy Y